Featured 13F manager
Opaleye Management Inc. James Silverman
Boston, MA 23 processed 13Fs on this site · 2021 Q3–2026 Q2
- $1.1B
- 58 Positions
- 2026 Q2
- +45.5% QoQ
- Top 5 46.8%
James Silverman files Opaleye Management Inc. as a Form 13F. The latest book is 2026 Q2 at $1.1B, up 45.5% QoQ, led by Liquidia, Eton Pharmaceuticals, and Harrow.
Portfolio
top 5 46.8% · top 10 64.8%
- LQDA - Liquidia 17.7%
- ETON - Eton Pharmaceuticals 9.4%
- HROW - Harrow 9.2%
- IRON - Disc Medicine 5.7%
- URGN - Urogen Pharma 4.8%
- APGE - Apogee Therapeutics 4.7%
- MGTX - Meiragtx 4.3%
- SLGL - Sol-Gel Technologies 3.3%
- RZLT - Rezolute 3.0%
- TGTX - Tg Therapeutics 2.7%
- IMMX - Immix Biopharma 2.2%
- CBIO - Crescent Biopharma 2.1%
- Other 30.9%
AUM over time
Book
| HROW - Harrow Health | 11.38% | Add +0.7% | 3,820,000 | $11.20 | $43M | +25,000 | −$12M |
| TGTX - Tg Therapeutics | 10.06% | Add +17.2% | 2,215,000 | $17.08 | $38M | +325,000 | +$22M |
| Acelyrin | 8.22% | Hold | 4,146,138 | $7.46 | $31M | — | — |
| RYTM - Rhythm Pharmaceuticals | 7.46% | Reduce −6.6% | 610,000 | $45.97 | $28M | −43,000 | +$13M |
| OCUL - Ocular Therapeutix | 7.20% | Reduce −6.2% | 6,070,000 | $4.46 | $27M | −398,000 | +$7M |
| Catalyst Pharmaceuticals | 5.70% | Add +4.3% | 1,257,200 | $17.05 | $21M | +52,200 | +$7M |
| Keros Therapeutics | 3.78% | Reduce −0.8% | 357,500 | $39.76 | $14M | −2,900 | +$3M |
| IDYA - Ideaya Biosciences | 2.95% | Hold | 311,500 | $35.58 | $11M | — | — |
| ETON - Eton Pharmaceuticals | 2.95% | Add +4.1% | 2,529,887 | $4.38 | $11M | +99,617 | +$947K |
| CRNX - Crinetics Pharmaceuticals | 2.91% | Reduce −16.9% | 307,500 | $35.58 | $11M | −62,500 | −$63K |
| ARVN - Arvinas | 2.89% | New | 263,700 | $41.16 | $11M | +263,700 | +$11M |
| CDXS - Codexis | 2.47% | Add +172.2% | 3,045,525 | $3.05 | $9M | +1,926,625 | +$7M |
| BHVN - Biohaven | 2.28% | Reduce −54.4% | 200,000 | $42.80 | $9M | −239,000 | −$3M |
| EWTX - Edgewise Therapeutics | 2.03% | Reduce −20.2% | 699,000 | $10.94 | $8M | −176,405 | +$3M |
| IOVA - Iovance Biotherapeutics | 1.94% | Add +47.0% | 897,000 | $8.13 | $7M | +287,000 | +$5M |
| ARQT - Arcutis Biotherapeutics | 1.68% | New | 1,960,000 | $3.23 | $6M | +1,960,000 | +$6M |
| FDMT - 4D Molecular Therapeutics | 1.66% | Hold | 308,500 | $20.26 | $6M | — | — |
| Marinus Pharmaceuticals | 1.63% | Reduce −3.5% | 563,500 | $10.87 | $6M | −20,500 | +$1M |
| PCVX - Vaxcyte | 1.50% | Hold | 90,000 | $62.80 | $6M | — | — |
| LQDA - Liquidia | 1.42% | Reduce −22.0% | 445,000 | $12.03 | $5M | −125,700 | +$2M |
| Protara Therapeutics | 1.34% | Hold | 2,692,594 | $1.88 | $5M | — | — |
| URGN - Urogen Pharma | 1.28% | Hold | 320,000 | $15.00 | $5M | — | — |
| XOMA - XOMA Del | 1.23% | Reduce −8.9% | 250,000 | $18.50 | $5M | −24,500 | +$757K |
| APLT - Applied Therapeutics | 0.97% | Add +22.3% | 1,092,500 | $3.35 | $4M | +199,500 | +$1M |
| RLMD - Relmada Therapeutics | 0.97% | Add +2823.3% | 877,000 | $4.14 | $4M | +847,000 | +$4M |
| TRVI - Trevi Therapeutics | 0.90% | Add +48.6% | 2,535,000 | $1.34 | $3M | +829,100 | −$322K |
| Jasper Therapeutics | 0.84% | New | 3,985,340 | $0.7890 | $3M | +3,985,340 | +$3M |
| INTC - Intellia Therapeutics | 0.80% | New | 99,000 | $30.49 | $3M | +99,000 | +$3M |
| NAMS - Newamsterdam Pharma | 0.79% | New | 265,388 | $11.17 | $3M | +265,388 | +$3M |
| LRMR - Larimar Therapeutics | 0.75% | Reduce −26.5% | 623,500 | $4.55 | $3M | −225,000 | −$515K |
| BBIO - Bridgebio Pharma | 0.75% | Add +9.0% | 70,000 | $40.37 | $3M | +40,927 | +$572K |
| Ventyx Biosciences | 0.75% | New | 1,140,000 | $2.47 | $3M | +1,140,000 | +$3M |
| Syros Pharmaceuticals | 0.74% | New | 359,370 | $7.79 | $3M | +359,370 | +$3M |
| Gossamer Bio | 0.72% | Reduce −37.3% | 2,982,200 | $0.9125 | $3M | −1,772,000 | −$1M |
| PTGX - Protagonist Therapeutics | 0.69% | New | 112,700 | $22.93 | $3M | +112,700 | +$3M |
| Kalvista Pharmaceuticals | 0.49% | Reduce −70.0% | 150,000 | $12.25 | $2M | −350,000 | −$3M |
| VSTM - Verastem | 0.46% | Hold | 211,400 | $8.14 | $2M | — | — |
| Nyxoah S A | 0.43% | Reduce −22.0% | 344,800 | $4.64 | $2M | −97,096 | −$2M |
| Morphosys AG | 0.38% | Reduce −88.0% | 145,000 | $9.90 | $1M | −1,064,380 | −$7M |
| PGEN - Precigen | 0.36% | Add +9.0% | 1,012,500 | $1.34 | $1M | +84,000 | +$38K |
| Sutro Biopharma | 0.34% | New | 301,491 | $4.29 | $1M | +301,491 | +$1M |
| CNTX - Context Therapeutics | 0.29% | New | 975,000 | $1.13 | $1M | +975,000 | +$1M |
| FULC - Fulcrum Therapeutics | 0.23% | New | 130,000 | $6.75 | $878K | +130,000 | +$878K |
| Aligos Therapeutics | 0.23% | New | 1,297,000 | $0.6640 | $861K | +1,297,000 | +$861K |
| Biodesix | 0.21% | Add +9.0% | 426,500 | $1.84 | $785K | +40,927 | +$572K |
| Kiniksa Pharmaceuticals · CLASS A | 0.17% | New | 37,500 | $17.07 | $640K | +37,500 | +$640K |
Exits / last held
not current holdings · last reported size, unchanged · gone vs 2023 Q3
| Stock | % of portfolio | Recent activity | Shares | Reported price* | Value | Share change | $ change |
|---|---|---|---|---|---|---|---|
| TELA - Tela Bio | 1.95% | Exit | 0 | $8.00 | $6M | −750,000 | −$6M |
| GERN - Geron | 1.32% | Exit | 0 | $2.12 | $4M | −1,915,000 | −$4M |
| Igm Biosciiences | 0.71% | Exit | 0 | $8.35 | $2M | −261,000 | −$2M |
| Tracon Pharmaceuticals | 0.28% | Exit | 0 | $0.1780 | $848K | −4,764,508 | −$848K |
| XERS - Xeris Biopharma | 0.24% | Exit | 0 | $1.86 | $725K | −390,000 | −$725K |
| Fortress Biotech | 0.19% | Exit | 0 | $0.2905 | $581K | −2,000,000 | −$581K |
| Kezar Life Sciences | 0.16% | Exit | 0 | $1.19 | $506K | −425,000 | −$506K |
Filings history
20 periods · normalized AUM · open a period for holdings
| Period | Holdings | AUM | QoQ | Form | Filed | Filing ID |
|---|---|---|---|---|---|---|
| 2026 Q2 | 58 | $1.1B | +45.5% | 13F-HR | 8/14/2026 | 000142050626001803 |
| 2026 Q1 | 54 | $759M | +0.1% | 13F-HR | 5/15/2026 | 000142050626001151 |
| 2025 Q4 | 54 | $758M | — | RESTATEMENT | 4/13/2026 | 000149315226016299 |
| 2025 Q4 | 54 | $758M | +7.2% | 13F-HR | 2/17/2026 | 000149315226007085 |
| 2025 Q3 | 43 | $707M | +41.7% | 13F-HR | 11/14/2025 | 000149315225023429 |
| 2025 Q2 | 41 | $494M | — | RESTATEMENT | 8/15/2025 | 000164117225024301 |
| 2025 Q2 | 41 | $499M | +11.1% | 13F-HR | 8/14/2025 | 000164117225023977 |
| 2025 Q1 | 45 | $449M | −21.4% | 13F-HR | 5/15/2025 | 000164117225010914 |
| 2024 Q4 | 39 | $571M | −4.8% | 13F-HR | 2/14/2025 | 000149315225006852 |
| 2024 Q3 | 44 | $600M | +37.0% | 13F-HR | 11/14/2024 | 000149315224045811 |
| 2024 Q2 | 51 | $438M | +0.2% | 13F-HR | 8/14/2024 | 000149315224032150 |
| 2024 Q1 | 52 | $459M | — | RESTATEMENT | 5/29/2024 | 000149315224021780 |
| 2024 Q1 | 51 | $437M | +16.2% | 13F-HR | 5/15/2024 | 000149315224019869 |
| 2023 Q4 | 47 | $376M | +22.5% | 13F-HR | 2/14/2024 | 000149315224006653 |
| 2023 Q3 | 41 | $307M | −26.6% | 13F-HR | 11/15/2023 | 000149315223041364 |
| 2023 Q2 | 47 | $418M | +25.1% | 13F-HR | 8/14/2023 | 000149315223028636 |
| 2023 Q1 | 41 | $334M | +16.0% | 13F-HR | 5/15/2023 | 000149315223016769 |
| 2022 Q4 | 40 | $288M | +19.0% | 13F-HR | 2/10/2023 | 000149315223004277 |
| 2022 Q3 | 42 | $242M | +9.0% | 13F-HR | 11/14/2022 | 000149315222032068 |
| 2022 Q2 | 47 | $222M | −31.1% | 13F-HR | 8/15/2022 | 000149315222022856 |
| 2022 Q1 | 45 | $322M | −31.6% | 13F-HR | 5/16/2022 | 000149315222013764 |
| 2021 Q4 | 39 | $471M | −12.0% | 13F-HR | 2/14/2022 | 000149315222004434 |
| 2021 Q3 | 48 | $535M | — | 13F-HR | 11/16/2021 | 000149315221028799 |
About
Opaleye Management Inc.
23 processed 13Fs on this site · 2021 Q3–2026 Q2